About
Bioinvent International Ab (F:BIX0) — investor relations, events, news, and company updates on 6ix.
Latest News
Feb 23 2026
BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting
Jan 5 2026
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
Dec 18 2025
BioInvent to Participate in Upcoming Investor Conference
Dec 8 2025
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025
Dec 7 2025
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025